Cursed Hollow 2026 starts in Phasmophobia via update 1.000.030, and for the first time, there are cosmetic rewards tied to it ...

STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...

AstraZeneca said it received European Union approval for its Imfinzi drug as a treatment for early-stage gastric and gastroesophageal cancers, expanding the label of one of its top-selling oncology ...

Samsung (SSNLF) users are growing suspicious. And for good reason. Users are jumpy whenever you mention anything related to security. For the users, it looks like anything that is coming up from the ...

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma. In an interview with CURE, Dr. Lakshmi Nayak, a ...

Timi is a news and deals writer who's been reporting on technology for over a decade. He loves breaking down complex subjects into easy-to-read pieces that keep you informed. But his recent passion ...

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system ...

The FDA has updated the safety labeling for axicabtagene ciloleucel (Yescarta, Kite Oncology) ­— a CAR T-cell therapy — extending its indication to include patients with relapsed or refractory primary ...

Google Warns Over 1 Billion Android Phones Are Now at Risk Your email has been sent If you’re using an older Android phone, Google has a message you probably don’t want to hear. More than 40% of ...

BOSTON — Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous ...

WASHINGTON, D.C. — Diabetes patients who use certain TRUE METRIX blood glucose meters are being urged to review updated safety instructions after manufacturer ...

– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified – Primary central nervous system lymphoma is ...